Benitec Biopharma enters ATM sales agreement for up to $75 million common stock offering

Benitec Biopharma Inc.

Up to $75M in common stock may be sold at-the-market through agent Leerink Partners.
Agent commission of 3.0% of gross proceeds; Company to reimburse certain expenses.
Net proceeds to fund product candidate development, working capital, and general corporate purposes.
Sales under existing shelf registration statement (S-3) filed March 5, 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.